Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

The increase in obesity and the aging of the population has lead to an increase in the incidence of type 2 diabetes. This has led to the development of new drugs such as thiazolidinediones (TZDs) which are Peroxisome Proliferator-Activated Receptor (PPAR-gamma) agonists, to treat type 2 diabetes. TZDs have recently been at the center of a controversy with regards to their cardiovascular safety. Pioglitazone is a TZD which has been shown to be effective in glycemic control by lowering insulin resistance. Pioglitazone also has beneficial effects on lipid metabolism and cardiovascular risk. The safety and efficacy of pioglitazone including its pleotropic effects are discussed at length in this article.

Original languageEnglish (US)
JournalClinical Medicine Insights: Endocrinology and Diabetes
Volume3
DOIs
StatePublished - Jan 2010

Keywords

  • Pioglitazone
  • cardiovascular
  • diabetes
  • efficacy
  • safety

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review'. Together they form a unique fingerprint.

Cite this